6QJB | pdb_00006qjb

Truncated Evasin-3 (tEv3 17-56)

• PDB DOI: https://doi.org/10.2210/pdb6QJB/pdb
• BMRB: 34354

• Classification: IMMUNE SYSTEM
• Organism(s): Rhipicephalus sanguineus
• Mutation(s): No 


• Deposited: 2019-01-24 Released: 2019-07-03 
• Deposition Author(s): Denisov, S.S., Ippel, J.H., Heinzman, A.C.A., Koenen, R.R., Ortega-Gomez, A., Soehnlein, O., Hackeng, T.M., Dijkgraaf, I.
• Funding Organization(s): Netherlands Organisation for Scientific Research

---

Experimental Data Snapshot

• Method: SOLUTION NMR
• Conformers Calculated: 100 
• Conformers Submitted: 20 
• Selection Criteria: structures with the lowest energy 

Literature

Tick saliva protein Evasin-3 modulates chemotaxis by disrupting CXCL8 interactions with glycosaminoglycans and CXCR2.

Denisov, S.S., Ippel, J.H., Heinzmann, A.C.A., Koenen, R.R., Ortega-Gomez, A., Soehnlein, O., Hackeng, T.M., Dijkgraaf, I.

(2019) J Biological Chem 294: 12370-12379

• PubMed: 31235521 
• DOI: https://doi.org/10.1074/jbc.RA119.008902
• Primary Citation Related Structures: 
  6QJB


• PubMed Abstract: 
  

  Chemokines are a group of chemotaxis proteins that regulate cell trafficking and play important roles in immune responses and inflammation. Ticks are blood-sucking parasites that secrete numerous immune-modulatory agents in their saliva to evade host immune responses. Evasin-3 is a small salivary protein that belongs to a class of chemokine-binding proteins isolated from the brown dog tick, Rhipicephalus sanguineus Evasin-3 has been shown to have a high affinity for chemokines CXCL1 and CXCL8 and to diminish inflammation in mice. In the present study, solution NMR spectroscopy was used to investigate the structure of Evasin-3 and its CXCL8-Evasin-3 complex. Evasin-3 is found to disrupt the glycosaminoglycan-binding site of CXCL8 and inhibit the interaction of CXCL8 with CXCR2. Structural data were used to design two novel CXCL8-binding peptides. The linear tEv3 17-56 and cyclic tcEv3 16-56 dPG Evasin-3 variants were chemically synthesized by solid-phase peptide synthesis. The affinity of these newly synthesized variants to CXCL8 was measured by surface plasmon resonance biosensor analysis. The K _d values of tEv3 17-56 and tcEv3 16-56 dPG were 27 and 13 nm, respectively. Both compounds effectively inhibited CXCL8-induced migration of polymorphonuclear neutrophils. The present results suggest utility of synthetic Evasin-3 variants as scaffolds for designing and fine-tuning new chemokine-binding agents that suppress immune responses and inflammation.

---

Organizational Affiliation: 
• Department of Biochemistry, University of Maastricht, Cardiovascular Research Institute Maastricht, 6229 ER, Maastricht, The Netherlands.
Institute for Cardiovascular Prevention, Ludwig Maximilian University, 80336, Munich, Germany.
Institute for Cardiovascular Prevention, Ludwig Maximilian University, 80336, Munich, Germany; German Center for Cardiovascular Research, 13316, Berlin, Germany; Partner Site Munich Heart Alliance, 80802 Munich, Germany; Department of Physiology and Pharmacology and Department of Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
Department of Biochemistry, University of Maastricht, Cardiovascular Research Institute Maastricht, 6229 ER, Maastricht, The Netherlands. Electronic address: [e-mail].

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content 

• Total Structure Weight: 4.31 kDa 
• Atom Count: 297 
• Modeled Residue Count: 40 
• Deposited Residue Count: 40 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Evasin-3	A	40	Rhipicephalus sanguineus	Mutation(s): 0
UniProt
Find proteins for P0C8E8 (Rhipicephalus sanguineus) Explore P0C8E8  Go to UniProtKB:  P0C8E8

Experimental Data & Validation

Experimental Data

• Method: SOLUTION NMR
• Conformers Calculated: 100 
• Conformers Submitted: 20 
• Selection Criteria: structures with the lowest energy 

Structure Validation

Entry History 

& Funding Information

Deposition Data

• Released Date: 2019-07-03 
Deposition Author(s): Denisov, S.S., Ippel, J.H., Heinzman, A.C.A., Koenen, R.R., Ortega-Gomez, A., Soehnlein, O., Hackeng, T.M., Dijkgraaf, I.

---

Funding Organization	Location	Grant Number
Netherlands Organisation for Scientific Research	Netherlands	723.013.009

Revision History  

• Version 1.0: 2019-07-03
  Type: Initial release
  
• Version 1.1: 2019-07-10
  Changes: Data collection, Database references
• Version 1.2: 2019-07-17
  Changes: Data collection
• Version 1.3: 2019-08-28
  Changes: Data collection, Database references
• Version 1.4: 2023-06-14
  Changes: Database references, Other
• Version 1.5: 2024-10-09
  Changes: Data collection, Database references, Structure summary